Filing Overview
Company: Consonance-HFW Acquisition Corp. (proposed post-combination name: Surrozen, Inc.)
Filing: Form 8-K filed August 10, 2021, reporting results of the extraordinary general meeting held the same day.
The filing concerns shareholder approval of the business combination with Surrozen, Inc. under the April 15, 2021 Business Combination Agreement. The transaction contemplated the domestication of CHFW from the Cayman Islands to Delaware, a name change to Surrozen, Inc., and the merger of Perseverance Merger Sub Inc. with and into Surrozen.
Financial Metrics and Capitalization
This 8-K does not report revenue, profit or loss, cash flow, operating margins, debt, cash balances, liquidity metrics, or other period-specific financial results.
- CHFW shareholders approved issuance of New Surrozen common stock to PIPE investors and Surrozen stockholders pursuant to the transaction agreements.
- The transaction materials referenced a condition requiring at least $100 million of aggregate cash proceeds from CHFW’s trust account and the PIPE financing, after specified unpaid expenses and liabilities, subject to redemption activity.
- The proposed New Surrozen capitalization included authorization for 500 million common shares and 10 million preferred shares.
- The filing does not state the final PIPE proceeds, redemption amount, post-transaction share count, or available cash.
Shareholder Vote and Material Changes
Holders of 9,945,364 ordinary shares, representing 83.34% of shares outstanding and entitled to vote as of July 9, 2021, were represented at the meeting.
| Matter | For | Against | Abstentions | Result |
|---|---|---|---|---|
| Business Combination Agreement | 9,712,408 | 176,605 | 56,351 | Approved |
| Domestication to Delaware | 9,712,408 | 176,605 | 56,351 | Approved |
| New organizational documents | 9,712,408 | 176,605 | 56,351 | Approved |
| Stock issuance | 9,712,208 | 176,805 | 56,351 | Approved |
| 2021 Equity Incentive Plan | 9,712,208 | 176,805 | 56,351 | Approved |
| 2021 Employee Stock Purchase Plan | 9,712,208 | 176,605 | 56,551 | Approved |
- Advisory governing-document proposals were also approved, including preferred-stock authorization, removal of stockholder action by written consent, and replacement of CHFW’s blank-check-company provisions.
- The adjournment proposal was not voted on because adjournment was unnecessary.
- The filing reports shareholder approval but does not confirm in this text that the merger had closed as of August 10, 2021.
Outlook, Risks, and Unusual Items
Management provided standard forward-looking statement disclosures rather than operating guidance or financial forecasts. No revenue, earnings, cash runway, or clinical-development guidance is provided.
- Completion of the business combination remained subject to applicable closing conditions, including the required cash proceeds threshold and the effects of shareholder redemptions.
- Identified risks included failure to consummate or integrate the transaction, litigation, unsolicited alternative transactions, disruption to operations, inability to retain key employees, inability to achieve anticipated benefits, failure to obtain or maintain a Nasdaq listing, transaction costs, and accounting and reporting issues related to SPAC warrants.
- The filing also cautions that actual events may differ materially from forward-looking statements and that CHFW was not obligated to update those statements.
Investor Verification Checklist
- Verify whether and when the merger and Delaware domestication ultimately closed.
- Verify final shareholder redemptions, PIPE proceeds, trust-account cash, transaction expenses, and compliance with the $100 million minimum-cash condition.
- Verify the final ownership percentages, share count, dilution from warrants and equity plans, and the securities’ post-closing Nasdaq listing.
- Review the Form S-4 declared effective July 15, 2021 and subsequent filings for Surrozen’s financial condition, clinical pipeline, liquidity, and material risks.
- Confirm the final legal name, ticker symbols, corporate governing documents, and terms of the equity incentive and employee stock purchase plans.